3.0.0 4899 2023-01-14T22:48:18Z 2023-01-14T22:48:18Z House H HR 2004-07-22 108 hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2004-07-22T18:30:12Z Referred to 2004-07-22T14:03:45Z hswm00 Ways and Means Committee House Standing Referred to 2004-07-22T14:03:50Z 2004-07-22 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2004-07-22 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hswm00 Ways and Means Committee 2004-07-22 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100-A 9 Library of Congress 2004-07-22 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2004-07-22 Introduced in House IntroReferral Intro-H 9 Library of Congress 2004-07-22 Introduced in House IntroReferral 1000 9 Library of Congress B000944 Rep. Brown, Sherrod [D-OH-13] Sherrod Brown D OH 13 N D000191 Rep. DeFazio, Peter A. [D-OR-4] PETER DEFAZIO D OR A. 4 2004-09-30 False Health Business records Commerce Corporation taxes Costs Drug advertising Drugs Federal advisory bodies Fines (Penalties) Foreign tax credit Government Operations and Politics Government paperwork Income tax Law Pharmaceutical research Prescription pricing Research and development Science, Technology, Communications Tax deductions Taxation Wholesale trade Health 00 2004-07-22 Introduced in House 2004-10-20T15:34:13Z Sustainable Drug Pricing Act - Amends the Public Health Service Act to require the Secretary of Health and Human Services to enter into agreements with the manufacturers of brand name prescription drugs for four-year terms to establish a maximum wholesale price for such drugs. Defines brand name prescription drugs as FDA-approved prescription drugs with market exclusivity. Requires such agreements to specify a liquidated penalty that is sufficient to deter violations for failure to maintain substantial compliance. Allows the Secretary to notify the Secretary of the Treasury that there is no longer an effective agreement in place if such a penalty is not paid. Requires the Secretary to monitor prices to ensure compliance. Allows the Secretary to require manufacturers entering into such agreements to cooperate with such monitoring and to allow the Secretary access to relevant financial records.

Requires the Secretary to establish the Advisory Panel on Drug-Price Negotiations to advise the Secretary on establishing prices. Requires the Panel to provide the Secretary with recommended drug prices for 25 drugs that the Panel considers important to the public health and for an additional 25 drugs that are the most commonly prescribed drugs in the United States.

Amends the Internal Revenue Code of 1986 to disallow: (1) a deduction for advertising, promotion, or marketing of brand name prescription drugs without a qualified pricing agreement in effect for the entire taxable year; and (2) a foreign tax credit for such drugs manufactured by the taxpayer without a qualified pricing agreement in effect for the entire taxable year.

]]> Sustainable Drug Pricing Act Display Title Sustainable Drug Pricing Act Official Title as Introduced To amend the Public Health Service Act and the Internal Revenue Code of 1986 to require agreements regarding the wholesale price of brand-name prescription drugs as a condition of the allowance of certain tax deductions and credits. Introduced in House IH Short Titles as Introduced Sustainable Drug Pricing Act Introduced in House 2004-07-22T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-108hr4899ih/xml/BILLS-108hr4899ih.xml 2004-07-22 Referred to the Subcommittee on Health. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.